Mi-2β promotes immune evasion in melanoma by activating EZH2 methylation
Open Access
- 9 March 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Abstract
Recent development of new immune checkpoint inhibitors has been particularly successfully in cancer treatment, but still the majority patients fail to benefit. Converting resistant tumors to immunotherapy sensitive will provide a significant improvement in patient outcome. Here we identify Mi-2β as a key melanoma-intrinsic effector regulating the adaptive anti-tumor immune response. Studies in genetically engineered mouse melanoma models indicate that loss of Mi-2β rescues the immune response to immunotherapy in vivo. Mechanistically, ATAC-seq analysis shows that Mi-2β controls the accessibility of IFN-γ-stimulated genes (ISGs). Mi-2β binds to EZH2 and promotes K510 methylation of EZH2, subsequently activating the trimethylation of H3K27 to inhibit the transcription of ISGs. Finally, we develop an Mi-2β-targeted inhibitor, Z36-MP5, which reduces Mi-2β ATPase activity and reactivates ISG transcription. Consequently, Z36-MP5 induces a response to immune checkpoint inhibitors in otherwise resistant melanoma models. Our work provides a potential therapeutic strategy to convert immunotherapy resistant melanomas to sensitive ones.Keywords
All Related Versions
This publication has 83 references indexed in Scilit:
- Apical role for BRG1 in cytokine-induced promoter assemblyProceedings of the National Academy of Sciences, 2005
- The Chromatin Remodeler Mi-2β Is Required for CD4 Expression and T Cell DevelopmentImmunity, 2004
- A hierarchical approach to all‐atom protein loop predictionProteins: Structure, Function, and Bioinformatics, 2004
- Role of Histone H3 Lysine 27 Methylation in Polycomb-Group SilencingScience, 2002
- On the Role of the Crystal Environment in Determining Protein Side-chain ConformationsJournal of Molecular Biology, 2002
- Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune DepigmentationJournal of Experimental Medicine, 1999
- Ikaros DNA-Binding Proteins Direct Formation of Chromatin Remodeling Complexes in LymphocytesImmunity, 1999
- New DNA sequence rules for high affinity binding to histone octamer and sequence-directed nucleosome positioningJournal of Molecular Biology, 1998
- Characterization of the CHD family of proteinsProceedings of the National Academy of Sciences, 1997
- Candidate metastasis-associated genes of the rat 13762NF mammary adenocarcinomaBreast Cancer Research and Treatment, 1993